Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 22, 2024 13:34 ET | Source: America’s Blood Centers

America's Blood Centers and ADRP Release Updated U.S. Blood Donation Statistics and Public Messaging Guide

Washington, DC, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Washington, DC – America’s Blood Centers (ABC), the national organization of community-based, independent blood centers that supply 60 percent of...
May 10, 2023 17:17 ET | Source: America’s Blood Centers

ADRP Announces Rebranding, Becomes the Association for Blood Donor Professionals

Washington, DC, May 10, 2023 (GLOBE NEWSWIRE) -- ADRP, the international division of America’s Blood Centers, today announced an extensive rebranding effort reflecting the organization’s growth and...
December 11, 2019 07:00 ET | Source: ProQR Therapeutics N.V.

ProQR Announces First Patient Dosed in Phase 1/2 Aurora Trial of QR-1123 for Autosomal Dominant Retinitis Pigmentosa

LEIDEN, Netherlands and CAMBRIDGE, Mass., Dec. 11, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA...
November 21, 2019 07:00 ET | Source: ProQR Therapeutics N.V.

ProQR Receives Orphan Drug Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa

LEIDEN, Netherlands and CAMBRIDGE, Mass., Nov. 21, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of...
September 09, 2019 07:00 ET | Source: ProQR Therapeutics N.V.

ProQR Receives Fast Track Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa

LEIDEN, Netherlands and CAMBRIDGE, Mass., Sept. 09, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of...
August 12, 2019 07:00 ET | Source: ProQR Therapeutics N.V.

ProQR Announces Clearance of IND to Start Clinical Trial of QR-1123 in Patients with Autosomal Dominant Retinitis Pigmentosa (adRP)

LEIDEN, Netherlands and CAMBRIDGE, Mass., Aug. 12, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of...
October 29, 2018 07:33 ET | Source: ProQR Therapeutics N.V.

ProQR In-licenses Worldwide Rights to Ophthalmology Drug Candidate from Ionis Pharmaceuticals

ProQR receives exclusive worldwide license for IONIS-RHO-2.5Rx, now QR-1123, for autosomal dominant retinitis pigmentosa (adRP), a rare inherited form of blindness with no approved therapy A first in...